CA-DEXCOM
26.4.2022 08:02:05 CEST | Business Wire | Press release
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase for the first time its new global portfolio of real-time continuous glucose monitoring (CGM) systems at the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) held April 27-30, 2022 in Barcelona. The expanded portfolio includes Dexcom ONE, Dexcom G6 and the upcoming Dexcom G7, a range of exceptionally accurate,* real-time CGM systems designed to empower more people living with diabetes than ever before.
“For two decades, Dexcom has tirelessly innovated to provide the most accurate, connected and accessible CGM technology to people with diabetes around the globe,” said Kevin Sayer, chairman, president and CEO of Dexcom. “Diabetes is not a one-size-fits-all condition—people deserve choice in how they manage their disease. We are excited to be able to provide three gold standard CGM systems that meet the differing needs of people with diabetes.”
Each system in the portfolio offers a different set of features and functionality for various needs across diabetes management; however, all three Dexcom systems eliminate burdensome scanning and painful fingerpricks† for calibration and diabetes treatment decisions.
The Dexcom Real-Time CGM Portfolio
System |
Dexcom G7
1
|
Dexcom G6
|
Dexcom ONE
|
Sensor |
|
|
|
Alerts |
|
|
|
Connectivity |
|
|
|
“Innovation, accuracy and reliability have always been at the core of our work to provide the diabetes community with the best technology possible,” said Chad Patterson, executive vice president of global marketing and product management at Dexcom. “It’s our priority to offer as many people access to the highest standard of care and this portfolio of real-time CGM systems delivers on that commitment.”
In addition to the introduction of Dexcom’s expanded product portfolio, key posters and research presented at ATTD continue to affirm the use of Dexcom CGM is central to optimal diabetes management. Some of these educational presentations may make claims exceeding those cleared by FDA for the labeling of these devices.
Dexcom CGM Accuracy, Performance and Feature Engagement:
- Presentation: “Elevating the standard of care in continuous glucose monitoring with Dexcom CGM.” Moderated by Partha Kar on Thursday, April 28, 2022, 15:00 – 16:30 CET in Hall 116. Speakers include: Žydrūnė Visockienė, MD, PhD; Nicholas Argento, MD, FACE; Lori Laffel, MD, MPH; Hood Thabit, MB, BCh, MRCP, MD, PhD; and Lalantha Leelarathna, MBBS, MRCP, MSc, PhD.
- Presentation: “Dexcom G6 real-time CGM use across the globe: Feature engagement and correlational outcomes.” Moderated by Keri Leone, MS, RD, CDCES on Friday, April 29, 2022, 09:00 – 10:00 CET in Hall 112. Speakers include: Giada Acciaroli, PhD; Robert Dowd, data scientist; Joost van der Linden, PhD; and Anand Iyer, PhD, MBA.
Dexcom Connectivity and Closed Loop Systems:
- Abstract: “Perioperative closed-loop insulin delivery versus standard insulin therapy: A randomised controlled parallel clinical trial in adults with Type 2 diabetes” (David Herzig).
- Abstract: “Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with Type 1 diabetes: a multicentre, multinational, randomised, crossover study” (Charlotte Boughton).
- Abstract: “Performance of Omnipod® 5 Automated Insulin Delivery System at specific glucose targets from 110-150mg/dL over three months in very young children with Type 1 diabetes” (Sarah MacLeish).
- Abstract: “Improvement in HbA1C after 8 weeks of Omnipod 5® Automated Insulin Delivery System use in adults with Type 2 diabetes: From injections to hybrid closed-loop therapy” (Anne Peters).
- Abstract: “A comparison of two hybrid closed-loop systems in Italian children and adults with Type 1 diabetes” (Marina Francesca).
- Abstract: “Glycemic outcomes by age and previous insulin delivery method in Control-IQ technology users: 9 months of CLIO study data” (Jordan Pinsker).
Health Outcomes, Economic Outcomes and Market Access:
- Presentation: “Dexcom G6 real-time CGM use in non-traditional clinical arenas: Hospital and pregnancy.” Moderated by Daniel Chernavvsky, MD on Saturday, April 30, 2022, 08:00 – 08:50 CET in Hall 112. Speakers include: Eileen Faulds, PhD, MS, RN, FNP-BC, CDCES and Anku Mehta, MD.
- Abstract: “The impact of real-time continuous glucose monitoring on treatment satisfaction in adults with Type 2 diabetes: Further findings from the MOBILE randomized clinical trial.” (David Price)
- Abstract: “Association between change in HbA1c and professional CGM use in adults with Type 2 diabetes on non-insulin therapies – a real-world evidence study” (Poorva Nemlekar).
- Abstract: “Reduction in diabetes-related hospitalization rates after real-time continuous glucose monitor (rtCGM) initiation” (Katia Hannah).
- Abstract: “Analysis of alert frequency and glycemic outcomes associated with expanding the default G6 high/low alert range” (Sarah Pickus).
- Abstract: “Cost-effectiveness of a real-time continuous glucose monitoring system versus self-monitoring of blood glucose in Type 2 diabetes patients on insulin in the United Kingdom” (Stephane Roze).
For more information about the 15th International Conference on Advanced Technologies and Treatments for Diabetes and to register to virtually attend the conference, visit https://attd.kenes.com/registration/ .
About DexCom, Inc.
DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com .
*Dexcom G6, Dexcom G7, and Dexcom ONE User Guides. To obtain the Instructions for use for these products, click here . Note that labeling may differ in different countries. |
† If your glucose alerts and readings from Dexcom ONE, Dexcom G6 or Dexcom G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. |
‡ To view a list of compatible smart devices, visit dexcom.com/compatibility |
†† Separate Follow App required. |
‡‡ Dexcom is working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as possible |
1 510(k) pending. Not available for sale in the United States. |
© 2022 Dexcom, Inc. Dexcom, Dexcom ONE, Dexcom G6, Dexcom G7 and Dexcom Clarity are registered trademarks of DexCom, Inc. in the U.S., and may be registered in other countries. All rights reserved. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425006053/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release
Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release
Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
